Cell MedX Aiming to Change Diabetes Care Forever - Diabetes Cure Treatment
http://cellmedx.com/
Cell MedX’s (OTCQB: CMXC) Diabetes is a devastating disease with enormous and expanding prevalence. Both type 1 and type 2 diabetes impose dramatic health burdens on sufferers along with difficult to manage and potentially fatal side effects. Until recently, I was unaware of the difficulty diabetes patients have in managing their disease and the number of people whose quality of life is severely impacted even after diagnosis and prescribed treatment. If managed properly, diabetes can be held in check and affected individuals can live long healthy lives. However, in many cases, current treatments make managing the disease an onerous process. A large percentage of diabetics do not properly understand how to effectively monitor their blood glucose levels so as to avoid devastating side effects. In some cases the body simply does not respond consistently or predictably to current treatments.
Cell MedX’s eBalance technology is designed to be a simple to use mobile tablet-sized device that can be used in a home or clinical setting. The proposed treatment regimen is 3 times a week for approximately 20 minutes. This regimen has been successful in initial examinations of the technology. In anticipation of the eventual commercialization of the technology, the company has engaged a European engineering firm to assist with the prototype’s design. Based on initial discussions and market comparisons, management believes it is realistic to introduce a device at a price point that will be desirable to insurers as a cost saving treatment.
Cell MedX’s (OTCQB: CMXC) Diabetes is a devastating disease with enormous and expanding prevalence. Both type 1 and type 2 diabetes impose dramatic health burdens on sufferers along with difficult to manage and potentially fatal side effects. Until recently, I was unaware of the difficulty diabetes patients have in managing their disease and the number of people whose quality of life is severely impacted even after diagnosis and prescribed treatment. If managed properly, diabetes can be held in check and affected individuals can live long healthy lives. However, in many cases, current treatments make managing the disease an onerous process. A large percentage of diabetics do not properly understand how to effectively monitor their blood glucose levels so as to avoid devastating side effects. In some cases the body simply does not respond consistently or predictably to current treatments.
Cell MedX’s eBalance technology is designed to be a simple to use mobile tablet-sized device that can be used in a home or clinical setting. The proposed treatment regimen is 3 times a week for approximately 20 minutes. This regimen has been successful in initial examinations of the technology. In anticipation of the eventual commercialization of the technology, the company has engaged a European engineering firm to assist with the prototype’s design. Based on initial discussions and market comparisons, management believes it is realistic to introduce a device at a price point that will be desirable to insurers as a cost saving treatment.
